Purchase this article with an account.
TAKUYA UTSUMI, Masahiko Shimura, Shigehiko Kitano, Taiji Sakamoto; Survey of TREATment for Diabetic Macular Edema (STREAT-DME) Study: Results by year from real world data in Japan. Invest. Ophthalmol. Vis. Sci. 2018;59(9):1057. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
In the treatment of Diabetic Macular Edema (DME), a multicenter retrospective registration survey of a 2-year treatment course in clinical practice has been conducted. Here, we report about a statistical analysis in terms of Visual Acuity (VA) from the viewpoint of comparing the year of starting interventional treatment.
Based on clinical records, 1171 treatment näive DME eyes which had been started interventional treatment from 2010 to 2014 for 2 years at 18 domestic facilities were registered. The VA, Central Retinal Thickness (CRT) and the required number of each intervention (anti-VEGF drugs, corticosteroid, macula photocoagulation or vitrectomy) during the clinical course were extracted.
Interventional treatment for 247 eyes was started before 2011, 219 eyes in 2012, 331 eyes in 2013, 313 eyes in 2014. The improvement of VA was -0.058±0.364 log MAR, -0.037±0.343 log MAR, -0.043±0.376 log MAR, -0.082±0.352 log MAR. The number of eye treated by anti-VEGF drugs was 111 (44.9%), 145 (66.2%), 199 (60.1%), 248 (79.2%).
From this real world data, the newer the year of starting interventional treatment, the better improvement of VA was obtained after a 2-year treatment course for DME in clinical practice. And the proportion of eyes treated by anti-VEGF injection has increased from year to year.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.
This PDF is available to Subscribers Only